Journal article
Safety of intracoronary human cord blood stem cells in a lamb model of infant cardiopulmonary bypass
CP Brizard, JYJ Looi, JJ Smolich, SB Horton, J Angerosa, NJ Elwood, S Pepe
Annals of Thoracic Surgery | Published : 2015
Abstract
Background One potential approach for advancing univentricular heart surgical palliation outcomes is by stem cell therapy to augment right ventricular function and muscle mass. Whether the stem cell-inclusive cord blood mononuclear cells (CBMNCs) are safe to perfuse into the coronary vasculature during neonatal cardiopulmonary bypass (CPB) is unknown. We evaluated the acute safety, functional effects, and fate of human CBMNCs in a novel model of coronary vasculature delivery in a lamb model of infant CPB. Methods Neonatal lambs were randomized in blinded fashion to receive control (n = 5) or human CD45+ CBMNCs (8 × 106 cells/kg body weight, n = 7) treatments during CPB. Aortic cross-clamp ti..
View full abstractGrants
Awarded by HeartKids Australia
Funding Acknowledgements
This work was supported in part by HeartKids Australia, The Royal Children's Hospital Foundation (RCH1000), The Phillip Bushel Foundation, and the Victorian Government's Operational Infrastructure Support Program to the Murdoch Childrens Research Institute.